Viemed authorizes share repurchase program
By HME News Staff
Updated 9:12 AM CDT, Tue June 10, 2025
LAFAYETTE, La. – Viemed Healthcare’s board of directors has authorized a share repurchase program, effective through June 2026. Under the share repurchase program, Viemed may purchase up to 1,976,441 common shares of the company from time to time in accordance with applicable securities laws, representing approximately 5% of the total issued and outstanding common shares as of March 31, 2025. “Our recent first quarter 2025 results and the increases in our 2025 guidance range midpoints demonstrate that we are executing well with strong underlying fundamentals in the business,” said Casey Hoyt, CEO. “We have a track record of disciplined capital allocation, with our latest example being the attractive acquisition of Lehan’s Medical that is expected to close in the third quarter of this year. Since our public listing, we have repurchased approximately 2.6 million shares, underscoring our commitment to executing on our capital allocation strategies. With no net debt and full availability on our $55 million credit facility, we have ample liquidity to improve shareholder value with a new share repurchase program while also funding our organic and inorganic growth initiatives.” Viemed intends to repurchase common shares through open market purchases, block purchases or otherwise in accordance with applicable securities laws. Subject to certain exceptions for block purchases, daily purchases will be limited to 25% of the average daily volume for the four calendar weeks preceding the date of purchase.
Comments